Patent · US Active

Compositions and methods for inhibiting viral replication

US8273868B2 · kind B2 · utility

5Cited by

8References

24Claims

0Family size

Assignee

Alnylam Pharmaceuticals, Inc. · US

Inventors

Matthias John · Hallstadt, DE
Stefan Limmer · Neudrossenfeld, DE
Hans-Peter Vornlocher · Bayreuth, DE
Roland Kreutzer · Weidenberg, DE

Key dates

Filing date	Dec 4, 2009
Grant date	Sep 25, 2012
Priority date	—
Expiry date	Jul 27, 2030

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2310/53
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to a double-stranded ribonucleic acid (dsRNA) having a nucleotide sequence which is less that 30 nucleotides in length and which is substantially identical to at least a part of a 3′-untranslated region (3′-UTR) of a (+) strand RNA virus, such as HCV, as well as pharmaceutical compositions comprising the dsRNA, together with a pharmaceutically acceptable carrier. The pharmaceutical compositions are useful for treating infections and diseases caused by the replication or activity of the (+) strand RNA virus, as well as methods for inhibiting viral replication.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.